Ipca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1703.45, up 0.49% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 23759.900390625. The Sensex is at 78574.27, up 0.56%. Ipca Laboratories Ltd has gained around 11.12% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 4.35% in last one month and is currently quoting at 23412.25, up 0.06% on the day. The volume in the stock stood at 4.6 lakh shares today, compared to the daily average of 6.54 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1701, up 0.55% on the day. Ipca Laboratories Ltd is up 53% in last one year as compared to a 9.67% jump in NIFTY and a 35.62% jump in the Nifty Pharma index.The PE of the stock is 61.59 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1656.9, up 1.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 23803.900390625. The Sensex is at 78735.73, up 0.05%. Ipca Laboratories Ltd has added around 8.08% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 3.31% in last one month and is currently quoting at 23008.35, up 0.8% on the day. The volume in the stock stood at 5.8 lakh shares today, compared to the daily average of 6.35 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1662.5, up 1.15% on the day. Ipca Laboratories Ltd is up 48.02% in last one year as compared to a 9.48% gain in NIFTY and a 37.57% gain in the Nifty Pharma index.The PE of the stock is 59.29 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories has received necessary approval for voluntary closure of its wholly owned subsidiary Ipca Pharmaceuticals SA de CV, Mexico. This wholly owned subsidiary incorporated in Mexico was not doing any business for the past several years. Voluntary closure of this wholly owned subsidiary will not have any impact on Company's business or financials.Powered by Capital Market - Live

Ipca Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 1591.25, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.25% on the day, quoting at 23745.85. The Sensex is at 78340.19, up 1.29%. Ipca Laboratories Ltd has slipped around 1.43% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has slipped around 5.27% in last one month and is currently quoting at 21544.15, up 1.67% on the day. The volume in the stock stood at 2.47 lakh shares today, compared to the daily average of 3.37 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1593.75, up 1.8% on the day. Ipca Laboratories Ltd is up 50.01% in last one year as compared to a 20.57% spurt in NIFTY and a 38.57% spurt in the Nifty Pharma index.The PE of the stock is 56.98 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories has fixed 27 November 2024 as record date for interim dividend for FY 2024-25. Powered by Capital Market - Live

Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 14 November 2024, has recommended a Interim dividend of Rs.2 per share (i.e.200%), subject to the approval of the shareholders.Powered by Capital Market - Live

Profit before tax surged 53.01% to Rs 344.83 crore in the September 2024 quarter from Rs 225.36 crore posted in Q2 FY24. EBITDA before forex gain/ (loss), other income and exceptional items stood at Rs 449.83 crore, registering a growth of 25% YoY. During the quarter, total formulations were at Rs 1,482.01 crore, up 13% YoY. Domestic stood at Rs 940.51 crore (up 11% YoY) and exports came in at Rs 541.50 crore (up 15.03% YoY) in Q2 FY25. On half yearly basis, the company's consolidated net profit grew 36.97% to Rs 421.71 crore on 22.89% increase in revenue from operations to Rs 4,447.53 crore in H1 FY25 over H1 FY24. Meanwhile, the firm's board has declared an interim dividend of Rs 2 per equity share for the financial year ended 2024-25. The firm had already fixed 28 October 2024 as record date for interim dividend and it will be paid on or before 10 December 2024. Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Powered by Capital Market - Live

Net profit of Ipca Laboratories rose 58.20% to Rs 229.48 crore in the quarter ended September 2024 as against Rs 145.06 crore during the previous quarter ended September 2023. Sales rose 15.78% to Rs 2354.90 crore in the quarter ended September 2024 as against Rs 2033.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales2354.902033.96 16 OPM %18.7517.73 - PBDT445.18354.99 25 PBT344.83264.65 30 NP229.48145.06 58 Powered by Capital Market - Live

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live

Ipca Laboratories has fixed 22 November 2024 as record date for payment of interim dividend that may be declared at the meeting of the Board of Directors of the Company scheduled to be held on 14 November 2024.Powered by Capital Market - Live